Health care and medical care<\/h2>\n
Medical care treats disease once it has appeared. Health care works on the condition of the body itself, so that it is better able to resist illness and to repair. Both are necessary, and they are not the same work.<\/p>\n
In the kidney the division is unusually stark, and it is worth stating without softening: no medicine raises kidney function.<\/strong> Blood pressure tablets lower blood pressure. Diabetes medicines lower blood sugar. Both are necessary and both prevent other catastrophes. Neither guarantees the kidney. A patient can have well-controlled numbers on paper for years while the function underneath them continues to fall.<\/p>\n The practical sequence follows from that, and it does not change. Relief first, from whatever is currently working. Correction alongside it. And then, as symptoms settle and repeat testing confirms it, the medicines come down. In that order, and never the other way round.<\/p>\n This is the section that matters most in this article, because the kidney is not forgiving in the way other organs are.<\/p>\n The kidney does not regenerate.<\/strong> The liver does. The kidney is built from a fixed number of filtering units \u2014 nephrons \u2014 roughly one to one and a half million in each kidney, two to three million in total, and the body makes no more of them. When kidney function declines, what that means is that nephrons have been lost. Those are not coming back.<\/p>\n So improvement here means two things, and they are different<\/strong>. It means recovering function in nephrons that are impaired but not destroyed \u2014 which is genuinely possible, and sometimes substantial. And it means stopping the loss of the ones that remain<\/strong>, which is possible at every stage and is the more important of the two.<\/p>\n The honest limits, stated plainly:<\/p>\n Against those limits sits the claim this practice makes, and the conditions attached to it are the whole point of it. Around ninety per cent of dialysis and transplantation could be avoided<\/strong> \u2014 but only where people know that kidney disease is silent, where decline is looked for early rather than waited for, and where what is found is then corrected rather than only medicated.<\/p>\n The reasoning is worth setting out, because it is not a claim that medicine does not work. Controlling symptoms with medication alone does not prevent renal damage.<\/strong> A well-controlled blood sugar in type 2 diabetes, a quiet lupus, a stable IgA nephropathy \u2014 in each of these the numbers on the page can look acceptable while nephrons continue to be lost underneath them.<\/p>\n And medication is not neutral here. Everything taken has to be cleared by the kidney, so every drug adds to its workload. Some do more than that: long-term medication can itself damage the kidney<\/strong> \u2014 immunosuppressants notably, but the diabetes and blood pressure medicines too.<\/p>\n So the answer is not more medicine, or better medicine. It is early detection, correction of what is actually driving the damage, and monitoring that continues afterwards.<\/strong> That is what the ninety per cent rests on, and without those three it does not hold.<\/p>\n Where detection is late \u2014 at stage 4 or stage 5 \u2014 the account changes, but it does not become nothing.<\/strong> Much of the lost function will not return. What remains available is to slow the decline, to delay dialysis or transplantation<\/strong>, and to improve how the person actually feels and lives in the meantime.<\/p>\n All of this is clinical experience across many years of practice, offered as experience rather than as trial data.<\/p>\n Asked which single organ matters most when treating a patient \u2014 with medicine or with correction \u2014 the answer here is the kidney, and the reasoning is practical rather than sentimental.<\/p>\n Every other organ leaves you room to work. Failing kidneys take the room away.<\/strong> Once function is low enough, protein has to be restricted, potassium has to be restricted, fluid has to be restricted, and electrolytes have to be watched. At exactly the point where the body most needs building material to repair with, you are no longer allowed to supply it.<\/p>\n That is the argument for finding it early. Not because early disease is more dangerous, but because early disease is the only stage at which you still have the freedom to treat it properly.<\/p>\n There is a second reason, and it applies to everyone taking anything: medicines are cleared by the kidney.<\/strong> Every additional drug adds to its workload. In a patient whose function is already falling, the prescription itself becomes part of the load.<\/p>\n Creatinine<\/strong> is the number patients are handed, and it is the least sensitive of the four. A person with a single kidney can have an entirely normal creatinine. By the time it is clearly abnormal, a great deal has already gone. And it is routinely dismissed in exactly the range where it should prompt action \u2014 1.2, 1.3 \u2014 because many laboratory reports print those as normal.<\/p>\n eGFR<\/strong> \u2014 the estimated glomerular filtration rate \u2014 is, in this practice’s view, a badly underused test. It is worth knowing that reference practice differs: in India a result below 90 is commonly flagged, while in a number of other countries nothing is flagged until it falls below 60. By 60 the patient is already at stage 3.<\/strong> The gap between those two thresholds is precisely the window in which something can still be done.<\/p>\n ACR \u2014 the urine albumin-to-creatinine ratio<\/strong> \u2014 is the single most useful early screening test in diabetic kidney disease, and it moves long before creatinine does. It is also, in ordinary practice, the one most often not ordered.<\/p>\n Red blood cells in the urine<\/strong> are the fourth, and they point somewhere different. Persistent urinary RBCs \u2014 even very few, but recurring \u2014 in someone whose eGFR is still acceptable suggest an immune process rather than a metabolic one, and that changes what should happen next.<\/p>\n The practical instruction that follows is simple: kidney function belongs in the annual blood panel, alongside the blood count and the lipids, from childhood onwards.<\/strong> Not because most people have kidney disease, but because the ones who do have no symptoms to warn them.<\/p>\n This distinction is not usually explained to patients, and almost everything about what to expect depends on it.<\/p>\n In diabetic and hypertensive nephropathy the damage is mainly vascular.<\/strong> High sugar injures the very small vessels of the glomerulus; high pressure does its own damage alongside. Blood vessels can recover. That is why, in early diabetic kidney disease, a creatinine of 1.1 to 1.3 can often be brought back below one, and why albumin leaking into the urine can stop.<\/p>\n In IgA nephropathy the nephron itself is damaged<\/strong>, by an immune process rather than a metabolic one. Function is correspondingly much harder to regain. The work is still worth doing \u2014 halting progression in an autoimmune nephropathy is a real result \u2014 but it is a different claim, and it should not be dressed up as the first one.<\/p>\n IgA nephropathy is an autoimmune disease, and it frequently begins in childhood after an infection. It presents either as nephritis<\/strong> \u2014 blood appearing in the urine \u2014 or as nephrotic syndrome<\/strong>, where protein is lost through the urine in quantity.<\/p>\n With proper treatment most children recover from that acute episode, and this is where the problem starts: the episode is treated, the child gets better, and everybody forgets it. But in some of them a slow degradation continues quietly underneath for years.<\/p>\n Any child who has had a nephritis or a nephrotic syndrome should have their kidney function followed afterwards<\/strong> \u2014 urine albumin and urinary red cells, repeated. If those keep appearing, the immune process is still running, and eGFR needs watching too.<\/p>\n One practical point on diagnosis. A biopsy is the only way to prove IgA nephropathy, and if immunosuppressive treatment is being considered then it is necessary, because you do not give those drugs on a guess. But a biopsy is not required in order to begin lifestyle correction.<\/strong> Where a patient is frightened of the procedure or would rather not have it, the correction can be started and the response watched on the same markers that would have been followed anyway. That is a decision for the patient and their family to make with their doctors.<\/p>\n Diabetes and blood pressure are the two commonest routes to chronic kidney disease, and the diabetic route contains something patients are rarely told.<\/p>\n In type 2 diabetes \u2014 which is ninety per cent or more of what is seen \u2014 insulin is not deficient. It is normal or high, and frequently very high.<\/strong> Yet a widespread belief, even in a state as health-aware as Kerala, is that type 2 diabetes involves insulin deficiency, and patients accept insulin injections on that basis.<\/p>\n That matters for the kidney specifically, because high circulating insulin causes sodium retention, and sodium retention raises blood pressure.<\/strong> So the sequence that plays out is: weight gain, then raised blood pressure, then diabetes \u2014 and then treatment that raises insulin further, whether by injection or by the many oral agents that push the pancreas to produce more. The high insulin is itself doing damage.<\/p>\n Alongside that, uncontrolled sugar injures the small vessels of the glomerulus directly. Both mechanisms point the same way, and both respond to the same correction.<\/p>\n Patients are often surprised that their blood pressure has anything to do with their kidneys. In fact the kidney is the organ that controls blood pressure.<\/p>\n It releases renin<\/strong>, which sets off the renin\u2013angiotensin\u2013aldosterone cascade \u2014 angiotensin built by the liver, aldosterone released by the adrenal gland sitting on top of the kidney \u2014 and that system governs not only pressure but blood volume and the excretion of sodium, potassium and calcium. Most blood pressure medicines work on precisely this mechanism.<\/p>\n Which produces a loop worth understanding. If atherosclerosis narrows the vessels supplying the kidney \u2014 and someone with narrowing in the heart’s arteries may well have it here too \u2014 flow to the kidney falls, renin rises, and blood pressure goes up. So new or suddenly worsening hypertension is a reason to look at the kidney, not only to prescribe for the pressure.<\/strong> Early on the function may still read normal; later the eGFR falls, or albumin appears, or red cells do.<\/p>\n The ranking below is from clinical experience in this practice, not from trial data, and is offered in that spirit.<\/p>\n Most<\/strong> \u2014 stages 1 and 2 with a metabolic cause: diabetic or hypertensive nephropathy, obesity-associated kidney disease, a creatinine sitting at 1.1 to 1.3, albumin beginning to appear in the urine. Here the damage is vascular, the nephron count is still largely intact, and this is where the disease is actually winnable.<\/p>\n Substantial<\/strong> \u2014 stage 3, and patients carrying diabetes and hypertension together with early kidney involvement. Function can improve, and the medication load can usually come down a long way.<\/p>\n Real, but bounded<\/strong> \u2014 IgA nephropathy and other immune nephropathies, and stage 4. The aim shifts from recovering function to arresting its loss. In late-stage disease even muscle mass becomes something to preserve rather than build.<\/p>\n Least<\/strong> \u2014 stage 5, and established renal failure. Function will largely not return at this point. What is still available is slowing the decline, delaying dialysis or transplantation<\/strong>, and improving quality of life day to day \u2014 which for many patients is the thing they most want. Once someone is established on dialysis, there is not enough working kidney left for this to be the answer.<\/p>\n Every one of these conditions \u2014 diabetic nephropathy, hypertensive nephropathy, obesity-associated kidney disease, IgA nephropathy \u2014 is an inflammatory<\/strong> disease. And inflammation is governed by fat rather than by protein, which is the opposite of where dietary advice usually starts.<\/p>\n Omega-6 fatty acids drive inflammation; omega-3 fatty acids drive the anti-inflammatory, healing side.<\/strong> A modern diet delivers a great deal of the first and very little of the second \u2014 largely through cooking oil, and through something most people believe to be straightforwardly healthy.<\/p>\n Nuts.<\/strong> Almonds, pistachios, cashews and the oils pressed from them are all high in omega-6. They are genuinely nutritious in other respects, which is exactly why the point needs making: eaten freely, on top of a diet already heavy in cooking oil, they push the balance further towards inflammation.<\/p>\n There is a further consequence worth drawing out. Very nearly every medicine used for these conditions is anti-inflammatory in one way or another<\/strong> \u2014 the pressure medicines, the asthma and allergy medicines, the painkillers, the steroids. They work by suppressing the omega-6 pathway. There is a parallel route to the same place, which is to supply enough omega-3 that the pathway is not running so hard in the first place. That is what the nutrition here is aimed at, and it is why correcting it can reduce what the prescription has to do.<\/p>\n This is not a general instruction to eat well. It is the mechanism the correction acts on.<\/p>\n Obesity travels with almost all of this, and the Indian thresholds are not the Western ones. A BMI of 23 is the upper end of normal for Asian populations, against 25 elsewhere<\/strong> \u2014 and in practice, at a BMI of only 20 or 21, fat percentage and waist circumference are frequently already high.<\/p>\n Which is why BMI is not what is followed here. The measurement that matters is the lean-to-fat ratio<\/strong> \u2014 with body fat around 15 per cent in men and 20 to 25 per cent in women as the target \u2014 and within that, visceral fat specifically. Reducing visceral fat is the common object across all of this: kidney stones, IgA nephropathy, diabetes, hypertension.<\/p>\n In advanced kidney disease the goal shifts. Muscle mass is then something to protect<\/strong> rather than to build, with fat mass the only thing being reduced.<\/p>\n People with kidney disease are rarely dealing with kidney disease alone. Perhaps a third arrive with arthritis or general weakness on top of it, and many have neuropathy, retinopathy or heart disease alongside. Fatigue is close to universal. Conventional exercise advice fails this group entirely.<\/p>\n The movement used here is done lying down and then sitting<\/strong>, working through the body in a set order, graded to what the person can actually manage. It is possible for someone waiting for bypass surgery, or who gets angina on minimal exertion. Nobody is pushed: the intensity is set by what the heart will tolerate, and in kidney disease the heart is usually compromised too.<\/p>\n Most people reach noticeably better flexibility within a month or two, with muscle mass protected while fat mass falls.<\/p>\n Nobody is asked to stop a medicine in order to start this. The sequence is the other way round.<\/p>\n Relief comes first, from whatever is currently working. Correction runs alongside it. Then, as symptoms settle and repeat testing confirms the change, the medicines come down \u2014 gradually, doctor-led, and driven by the reports rather than by how somebody feels. No dose is changed alone.<\/strong><\/p>\n In earlier-stage kidney disease \u2014 through stage 3, and into stage 4 where eGFR is still above 20 \u2014 most patients come off the great majority of their diabetes and blood pressure medication within about a month. An HbA1c in the tens can come down towards six over three months where the protocol is followed closely.<\/p>\n One medicine is worth describing exactly, because it is used differently here. The SGLT2 inhibitors<\/strong> work by pushing glucose out through the urine, and they are the class preferred in this setting because they do not drive weight gain the way many diabetes drugs do. But they are used occasionally \u2014 once or twice a week, around a heavier meal \u2014 and not daily.<\/strong> The reason is specific to this organ: on that medicine the urine is persistently sweet, which is an invitation to bacteria. And every medicine, this one included, has to be cleared by the kidney.<\/p>\n A stone forms when crystals come out of solution in the urine \u2014 usually oxalate or uric acid \u2014 because there is too little water, too much solute, or both. As it grows it damages the kidney around it and can obstruct flow.<\/p>\n Modern treatment is effective: shock-wave therapy breaks the stone up and it passes. What it does not do is change why the stone formed.<\/strong> So the diet stays the same, and the stone comes back, and it is treated again. Patients arrive here having had the procedure three or four times, by which point creatinine is no longer normal.<\/p>\n What changes the pattern is unremarkable and effective: enough water, identifying which crystal type is forming and adjusting the diet to it, reducing the toxin load, and bringing visceral fat down.<\/p>\n There is a further reason that matters specifically to stone-formers. The metabolic waste of medicines is excreted through the urine as well, and it adds to the solute load<\/strong> \u2014 which is exactly what invites crystals to form. So in someone who makes stones, bringing blood sugar, blood pressure and cholesterol under control without<\/strong> medication counts for more than it does in most patients: it removes solute as well as treating the cause, and it works alongside the increase in fluid intake rather than instead of it.<\/p>\n Polycystic kidney disease is inherited \u2014 autosomal dominant, so a child of an affected parent carries a high chance of it \u2014 and cysts progressively damage the surrounding kidney. It is usually picked up on an ordinary abdominal ultrasound, which remains one of the most informative and least expensive tests available.<\/p>\n Being genetic does not make lifestyle correction irrelevant. It makes it more important. The inherited disease sets the floor; everything else added on top decides how fast you reach it.<\/strong> Keeping blood pressure controlled, not becoming diabetic, and not becoming obese are the things that determine how long the remaining function lasts.<\/p>\n A pattern worth putting in front of parents. Children on repeated courses of antibiotics for recurrent respiratory infection \u2014 once or twice a month in some cases \u2014 are worth asking a different question about: what was eaten in the two or three days before it started. Colours, preservatives, and food heavy in omega-6.<\/p>\n Because there is a category of food reaction that does not announce itself. No itching, no weals, nothing immediate<\/strong> \u2014 but a delayed immune response, to commonly eaten foods including nuts, rice and wheat, and notably to chana and cowpea, which in this practice’s experience perhaps fifteen to twenty per cent of the local population reacts to. What it produces instead is recurrent infection, headache, eczema, psoriasis \u2014 and in some patients a slow decline in kidney function.<\/p>\n That is one of the candidate mechanisms behind slowly progressive IgA nephropathy, and it is testable. It is also the kind of thing that is never found unless somebody thinks to look.<\/p>\n What follows is one patient, described to show how the pieces move together. It is not a typical result and is not offered as one \u2014 what any individual can expect depends on how much working kidney remains.<\/p>\n He came in with diabetes and high blood pressure of long standing, an eGFR that had fallen to around sixty, and an HbA1c of twelve. He was on insulin and on several other diabetes medicines. On the numbers he was at the point where the door starts closing.<\/p>\n The insulin and the diabetes medicines came off early, under supervision and on repeat testing, with only occasional use of a single agent around heavier meals. Over ninety days the HbA1c came down from twelve to about six. The eGFR did not merely stabilise; it rose, into the nineties<\/strong> \u2014 and the albumin that had been leaking into his urine stopped.<\/p>\n What made that possible was where he was caught.<\/strong> The damage was vascular and metabolic rather than immune, and enough nephrons were still alive to recover. Had the same patient arrived two or three years later, the honest account would have been a different one: hold the line, protect what is left, and avoid dialysis for as long as possible. That is a good outcome too. It is simply not this one.<\/p>\nWhat “improvement” means here \u2014 and what it does not<\/h2>\n
\n
Why the kidney is the organ that decides<\/h2>\n
The four numbers, and why creatinine alone misleads<\/h2>\n
![\"Four](\"https:\/\/www.lcchospital.com\/wp-content\/uploads\/2026\/08\/cslc-cap-kidney-four-numbers.png\")
Two kinds of damage, and why the difference decides the outcome<\/h2>\n
![\"Diagram](\"https:\/\/www.lcchospital.com\/wp-content\/uploads\/2026\/08\/cslc-cap-kidney-two-kinds-of-damage.png\")
IgA nephropathy, and the childhood episode nobody follows up<\/h2>\n
Diabetes, and the part played by insulin itself<\/h2>\n
Blood pressure and the kidney are one system<\/h2>\n
Where this does most, and where it does least<\/h2>\n
![\"Ranking](\"https:\/\/www.lcchospital.com\/wp-content\/uploads\/2026\/08\/cslc-cap-kidney-where-it-helps.png\")
The fats decide the inflammation<\/h2>\n
Obesity, visceral fat and the ratio that is actually tracked<\/h2>\n
Movement, when the patient is exhausted<\/h2>\n
Medication \u2014 how reduction actually happens<\/h2>\n
Kidney stones, and why they keep coming back<\/h2>\n
Polycystic kidney disease<\/h2>\n
Children, and the reactions that do not look like allergies<\/h2>\n
One patient’s course<\/h2>\n
The four optimization domains<\/h2>\n
\n\n
\n \nDomain<\/th>\n What it addresses<\/th>\n<\/tr>\n<\/thead>\n \n Optimal nutrition<\/td>\n Supplying the full range of nutrients the body needs in order to repair, in a nutrient-dense form with minimal additives. In kidney disease the balance of fats acts directly on the mechanism, since these are inflammatory diseases \u2014 omega-3 raised and supplied alongside the antioxidants and minerals that protect it. Where function is reduced, protein, potassium and fluid are handled according to what the kidney can still clear.<\/td>\n<\/tr>\n \n Optimal exercise<\/td>\n Gentle, segmental movement performed lying down and then sitting, graded to what the person can manage, with intensity set by what the heart will tolerate. No gym or equipment, so it remains possible with fatigue, neuropathy or cardiac disease. In advanced kidney disease the aim is to preserve muscle mass while fat mass falls.<\/td>\n<\/tr>\n \n Rest and sleep<\/td>\n Recovery, without which repair and metabolic regulation do not function well however good the nutrition. Disturbed sleep and insulin resistance worsen one another, and both bear on the kidney.<\/td>\n<\/tr>\n \n Reduced toxin load<\/td>\n Lowering avoidable exposure \u2014 colourings, preservatives and taste enhancers first, then alcohol and tobacco. This matters more here than anywhere else in the series: a kidney with reduced function is already struggling to clear ordinary waste, and every unnecessary compound, medicines included, is added to that work.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n